Esperion Therapeutis.Inc. Stock
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Pros and Cons of Esperion Therapeutis.Inc. in the next few years
Pros
Cons
Performance of Esperion Therapeutis.Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Esperion Therapeutis.Inc. | -3.810% | -2.985% | -30.256% | 60.753% | -38.275% | -92.220% | -95.406% |
| Ardelyx Inc. | 3.600% | -1.640% | -12.849% | 41.749% | 3.737% | -16.140% | - |
| Salarius Pharmaceuticals Inc. | 1.400% | 3.333% | 6.373% | -63.833% | -21.802% | -98.281% | -99.993% |
| Brainstorm Cell | -5.760% | -2.456% | -18.607% | -82.011% | 114.009% | -83.339% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Based on the provided financial statements, it is clear that Esperion (ESPR) has been facing some significant financial challenges. Although the company operates in the lucrative Biotechnology & Medical Research industry, its financial performance suggests that it is underperforming in several key areas. However, there are also some positive indicators that could signal potential growth and improvement in the future.
Rising revenues: Over the years, Esperion has seen an increase in total revenues. In 2020, the company reported a total revenue of $227.5 million that surged to $78.4 million in 2021, and a slight uptick to $75.47 million in the subsequent year. This growth indicates that the company is successful in addressing market demand.
Gross profit growth: Esperion's gross profit increased from $225 million in 2020 to $64.2 million in 2021, followed by further growth to $48.5 million in 2022. This growth in gross profits suggests that the company is becoming more efficient in its operations.
Comments